Comprehensive market insights across over 40 indications in dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology, providing financial firms with the tools to evaluate brand launches and project market evolution.
EXTON, PA, Sept. 25, 2024 (GLOBE NEWSWIRE) — Spherix Global Insights, a leading independent market intelligence and advisory firm, is expanding its specialized offerings to buy-side financial firms within the pharmaceutical and biotech sectors. For years, top pharmaceutical manufacturers have relied on Spherix’s data to shape their brand strategies—now, this same critical intelligence is available to financial firms seeking deeper insights into market dynamics.
As the Q3 earnings season approaches, Spherix offers unparalleled data integrity, independently sourced insights, and market intelligence across critical therapeutic areas. Over the past eight years, Spherix has meticulously tracked both emerging and established indications across seven specialty fields, leveraging a vast proprietary network of physicians and key opinion leaders. This research has become indispensable to commercial teams at biopharmaceutical companies and is frequently referenced by news media and investors alike.
Quarterly tracking of market dynamics in rapidly evolving areas like IgA nephropathy, atopic dermatitis, generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) provides critical validation—or recalibration—of market assumptions surrounding the impact of new entrants. In addition, monthly monitoring of key performance indicators for over 85 recently launched brands delivers real-time insights into market trends, enabling both pharmaceutical companies and investors to evaluate the potential success and impact of new therapies.
“We follow the companies you’re putting your money into and provide independent data that help guide your investments,” said Dan Barton, CEO of Spherix Global Insights. “Our insights are designed to not only highlight emerging market trends but also to help investors navigate the ever-evolving market dynamics within the Life Sciences space.”
With a steadfast commitment to independence, Spherix ensures that its clients receive unbiased market intelligence. Investors can access the same insights that pharmaceutical and biotech clients have long relied on to inform their business decisions.
For a complete list of all products and indications covered visit the Spherix portal at https://clientportal.spherixglobalinsights.com
Comprehensive Coverage Across Core Therapeutic Areas
Spherix provides market intelligence across key therapeutic areas, dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix market intelligence and advisory services offerings include:
RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.
Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.
Specialties and Indications Included in Spherix Coverage:
| Specialty Market | Indications Covered and Tracked |
| Dermatology | Alopecia Areata (AA) Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS) Plaque Psoriasis (PsO) Prurigo Nodularis (PN) Vitiligo |
| Gastroenterology | Celiac Disease Clostridioides Difficile (Cdiff) Crohn’s Disease (CD) Eosinophilic Esophagitis (EoE) Irritable Bowel Syndrome (IBS) MASLD/MASH (previously NAFLD/NASH) Primary Biliary Cholangitis (PBC) Ulcerative Colitis (UC) |
| Rheumatology | ANCA-associated Vasculitis Ankylosing Spondylitis and Non-radiographic Axial Spondylitis (AS, nr-axSpA) Cutaneous Lupus Erythematosus (CLE) Dermatomyositis (DM) Giant Cell Arteritis (GCA) Lupus Nephritis (LN) Polymyalgia Rheumatica (PMR) Psoriatic Arthritis (PsA) Rheumatoid Arthritis (RA) Sjögren’s Syndrome (SjS) Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SSc) |
| Nephrology | Alport Syndrome Chronic Kidney Disease (CKD) Complement 3 Glomerulopathy (C3G) Diabetic Kidney Disease (DKD) Dialysis Focal Segmental Glomerulosclerosis (FSGS) Glomerular Disease and Nephritis Hyperkalemia Hyperphosphatemia IgA Nephropathy (IgAN) Lupus Nephritis (LN) Membranous Nephropathy (MN) Polycystic Kidney Disease (ADPKD) Renal Anemia |
| Neurology | Alzheimer’s Disease (AD) Amylotrophic Lateral Sclerosis (ALS) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epilepsy Generalized Myasthenia Gravis (gMG) Huntington’s Disease (HD) Migraine Multiple Sclerosis (MS) Parkinson’s Disease (PD) |
| Ophthalmology | Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Dry Age-related Macular Degeneration (AMD) Geographic Atrophy (GA) Gene Therapies in Retinal Disorders Neovascular Age-related Macular Degeneration (nAMD) |
| Hematology | ANCA-associated Vasculitis Ankylosing Spondylitis and Non-radiographic Axial Spondylitis (AS, nr-axSpA) Cutaneous Lupus Erythematosus (CLE) Dermatomyositis (DM) Giant Cell Arteritis (GCA) Lupus Nephritis (LN) Polymyalgia Rheumatica (PMR) Psoriatic Arthritis (PsA) Rheumatoid Arthritis (RA) Sjögren’s Syndrome (SjS) Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SSc) |
About Spherix Global Insights
Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
CONTACT: Jake Pirri, Financial Planning and Services Spherix Global Insights 4848794284 jake.pirri@spherixglobalinsights.com
- GlobalFoundries Announces Conference Call to Review Second Quarter 2025 Financial Results - July 2, 2025
- Terminal Tractor Market worth $2.25 billion by 2032, Globally, at a CAGR of 5.5%, says MarketsandMarkets™ - July 2, 2025
- EC-Council Announces a New Era in Cybersecurity Talent Development with Upgraded SOC and DevSecOps Credentials - July 2, 2025
